The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

Leukemia

Volumn 25, Issue 7, 2011, Pages 1122-1127

  Burnett, A K ^a   Hills, R K ^a   Hunter, A ^b   Milligan, D ^c   Kell, J ^d   Wheatley, K ^e   Yin, J ^f   McMullin, M F ^g   Cahalin, P ^h   Craig, J ⁱ   Bowen, D ^j   Russell, N ^k  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^h BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

ⁱ ADDENBROOKE S HOSPITAL   (United Kingdom)

^j LEEDS GENERAL INFIRMARY   (United Kingdom)

^k NOTTINGHAM CITY HOSPITAL   (United Kingdom)

more..

Author keywords

acute myeloid leukaemia; arsenic trioxide; clinical trials

Indexed keywords

ALANINE AMINOTRANSFERASE; ARSENIC TRIOXIDE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEART DISEASE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUTH DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; COMORBIDITY; CYTARABINE; DISEASE-FREE SURVIVAL; DRUG-INDUCED LIVER INJURY; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; GASTROINTESTINAL DISEASES; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 79960245246     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.59     Document Type: Article

References (13)

1. Menzin J, Lang K, Earle C, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002; 162: 1597-1603. (Pubitemid 34773427)
2. Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglund M, Karlsson K et al. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia 2006; 20: 42-47.
3. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114-1124. (Pubitemid 46435390)
4. Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M et al. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008; 113: 2504-2511.
5. Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leukemia Res 2004; 9: 909-919. (Pubitemid 38960752)
6. Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol 2002; 116: 555-563. (Pubitemid 34178654)
7. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110: 4606-4613. (Pubitemid 351377830)
8. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145: 598-605.
9. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendation of the International Working Group for diagnosis standardisation, of response criteria treatment outcomes and reporting standards for therapeutic trials in acute myeloid leukaemia. J Clin Oncol 2003; 21: 4642-4649. (Pubitemid 46594039)
10. Royston P, Parmar MKB, Qian W. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med 2003; 22: 2239-2256. (Pubitemid 36926938)
11. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Brit J Haematol 2007; 136: 624-627. (Pubitemid 46148199)
12. Burnett AK, Hills RK, Milligan DW, Kell WJ, Wheatley K, Virchis AE. Low dose Ara-C versus Low dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 'Pick a Winner' comparison. Blood (ASH Annual Meeting Abstracts) 2008; 112: 2962.
13. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.